Pluristem Therapeutics Inc. news

   Watch this stock
Showing stories 1 - 10 of about 57   

Articles published

PSTI 2.93 -0.01 (-0.34%)
price chart
Pluristem Therapeutics, Inc. (PSTI) in Focus: Stock Up 7.4%
Pluristem Therapeutics, Inc. (PSTI - Snapshot Report) was a big mover last session, as the company saw its shares rise over 7% on the day.
Pluristem Therapeutics, Inc. (PSTI) in Focus: Stock Up 7.4% - Tale of the Tape
Pluristem Therapeutics, Inc. ( PSTI ) was a big mover last session, as the company saw its shares rise over 7% on the day.
Pluristem rebuffs patent challenge (PSTI)  Seeking Alpha (registration)
Pluristem Therapeutics Lifted to "Outperform" at Zacks (PSTI)  WKRB News
Related articles »  
Coverage Initiation Report Focuses on Pluristem Therapeutics
NEW YORK, NY--(Marketwired - Oct 1, 2014) - Pluristem Therapeutics Inc. ( NASDAQ : PSTI) ( TASE : PLTR) is the subject of a new in-depth initiation coverage report by Acceleron Equity Research.
Related articles »  
Zacks Upgrades Pluristem Therapeutics to "Outperform" (PSTI)
Pluristem Therapeutics Inc. logo Pluristem Therapeutics (NASDAQ:PSTI) was upgraded by Zacks from a �neutral� rating to an �outperform� rating in a note issued to investors on Monday.
Pluristem Therapeutics (PSTI) Releases Quarterly Earnings Results  Watch List News (press release)
Latest Developments: Pluristem Therapeutics Inc. (NASDAQ:PSTI), Vale SA ...  Market News Call
Related articles »  
Stocks Alert- Pluristem Therapeutics Inc. (NASDAQ:PSTI), Tetraphase ...
Las Vegas, NV - October 08, 2014 - (TechSonian) - Pluristem Therapeutics Inc. (NASDAQ:PSTI) is a bio-therapeutics company engaged in the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe ...
Pluristem Therapeutics Rating Increased to Outperform at Zacks (PSTI)  Mideast Time
Market Highlight: Pluristem Therapeutics (PSTI), Christopher & Banks ...  USMarketsDaily (blog)
Related articles »  
Lessons from people who paid off $100000
HAIFA, Israel, Oct. 27, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-derived cell therapy products, announced today that researchers at Case Western Reserve University will conduct ...
Case Western Reserve University to Study Pluristem's PLX-RAD Cells in ...  MarketWatch
Related articles »  
Pluristem Advances Its Second Major Cell Therapy Product Line From ...
Pluristem Therapeutics Inc. PSTI, +0.34% (tase:PLTR), a leading developer of placenta-based cell therapy products, announced today that it has completed development of its second major product line, and can now begin manufacturing the cells on a ...
Pluristem Therapeutics (PSTI) Will Begin Manufacturing of Second Major ...  StreetInsider.com (subscription)
Related articles »  
Shining on Major News: GoPro (NASDAQ:GPRO), Yahoo! Inc. (NASDAQ:YHOO ...
Pluristem Therapeutics Inc. (NASDAQ:PSTI) on 21st October has completed development of its second major product line, and can now begin manufacturing the cells on a large-scale at its state-of-the art facility in order to meet demand for anticipated ...
Why Japan is Crucial to the Future of Stem Cell Research
TLSR: In mid-September, Pluristem Therapeutics Inc. (PSTI) , an Israeli company, said it was going to pursue a development strategy in Japan.
The Spectranetics Corporation (SPNC) in Focus: Stock Soars 13.4%
Some better-ranked stocks in the broader health care sector include Valeant Pharmaceuticals International, Inc. (VRX - Analyst Report), Mylan, Inc. (MYL - Analyst Report) and Pluristem Therapeutics, Inc. (PSTI - Snapshot Report), each carrying a Zacks ...
The Spectranetics Corporation (SPNC) in Focus: Stock Soars 13.4% - Tale of ...  Nasdaq
Related articles »